Description of Carbiroid
Carbiroid tablet is a round, pink, uncoated tablet with deep convex faces. It contains Carbimazole as its active ingredient.
In addition, it also contains inactive ingredients called excipients in sufficient quantities.
Actions and pharmacology
Carbimazole is an antithyroid agent which depresses the formation of thyroid hormone.
Its main effect is to reduce the formation of iodotyrosines and hence of tri-iodothyronine and thyroxine.
It is rapidly absorbed orally and almost completely excreted in the urine in 24 hours as the metabolite methimazole.
Indications of Carbiroid
Carbiroid is used for the treatment of hyperthyroidism, including prior to surgery or radiotherapy; as well as concomitant therapy with radio lodine treatment.
Contraindications
Breast feeding should not be undertaken by lactating patients.
Precautions
- Caution in patients with bone marrow depression, hepatic function impairment or infection.
- Use of minimum effective dose during pregnancy is recommended.
- It should be given with caution if there is any degree of tracheal obstruction. Cross-sensitivity with other antithyroid agents may sometimes occur.
Warning
Carbimazole may cause white cell disorders such as neutropenia and agranulocytosis, which may be fatal if treatment with carbimazole is not stopped promptly.
These reactions usually occur during the first 3 months of therapy. and in most cases, are reversible on stopping treatment.
Since agranulocytosis can develop very rapidly, periodic leukocyte counts alone may not be effective in the early detection of these reactions.
During treatment with carbimazole :
- The patient should be asked to immediately report signs and symptoms suggestive of infection, e.g. sore throat, fever, mouth ulcers.
- A white cell count should be performed if there is any clinical evidence of infection. 3. The drug should be stopped promptly if there is clinical or laboratory evidence of neutropenia.
MAIN SIDE/ADVERSE EFFECTS
Skin rash, nausea, headache, gastrointestinal upsets, joint pains, agranulocytosis.
Drug interactions and incompatibilities
Concurrent use with anticoagulants and heparin is not recommended.
Concurrent use with agranulocytosis producing medications may increase the risk of agranulocytosis.
Overdose
Clinical features: Single overdose does not appear to cause significant symptoms; treatment is not required.
Dosage and administration
Adults: Oral, 30-60 mg daily in divided doses every 8 hours, the dosage being gradually reduced to the smallest effective dose, usually 5 to 20 mg daily.
Children: Oral, 2.5-10 mg every 8 hours, the dosage being reduced gradually according to the clinical response.
Note: The information given here is limited. For further information consult your doctor or pharmacist.
Store below 25°C. Protect from light.
Storage Presentation/Packing: Tablet 5 mg x 100’s, 500’s, 1000’s.